U.S. FDA Bans Sales of Unapproved Wegovy-Like Products
Targeting sellers of substitute products such as Hims & Hers
"To protect consumers...legal action for violations"
The U.S. Food and Drug Administration (FDA) has banned the sale of low-cost substitute products compounded with the same ingredient as the oral obesity drug Wegovy.
On the 7th (local time), FDA Commissioner Martin Makary said, "We will take firm measures to ensure that the active ingredient of the obesity treatment glucagon-like peptide-1 (GLP-1) is not used in compounded drugs that are mass-marketed." He went on to point out, "Telehealth companies such as Hims & Hers are conducting large-scale marketing campaigns that promote compounded drugs, which have not been approved by the FDA, as if they were alternative versions similar to FDA-approved drugs." Hims & Hers is a telehealth company headquartered in San Francisco, United States.
Commissioner Makary stressed, "Companies cannot advertise compounded products that have not been approved by the FDA as generics or as the same products as FDA-approved drugs," adding, "They also cannot state that compounded drugs use the same active ingredient as FDA-approved drugs." He warned that if companies do not properly correct violations, the agency plans to take additional legal actions beyond seizure and injunction orders.
The FDA's announcement came just one day after Hims & Hers said it would launch at a low price a compounded product that contains the same active ingredient as Danish pharmaceutical company Novo Nordisk's oral Wegovy tablet. On the 5th, when announcing the product launch, Hims & Hers introduced it by saying, "This once-daily pill contains the same active ingredient as Wegovy." The company released the product using a compounding method that customizes the dosage of existing pharmaceutical ingredients to meet the needs of individual patients. The FDA allows compounding for patient-specific prescriptions without separate approval.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In early January, Novo Nordisk began selling the oral tablet form of Wegovy in the U.S. market. The price of the original Wegovy product was set at a minimum of 149 dollars per month (about 220,000 won), while Hims & Hers announced that it plans to sell its product for 49 dollars per month (about 70,000 won) in the first month after launch and 99 dollars per month (about 140,000 won) thereafter. The way Hims & Hers sells its compounded drug, which has not been approved by the FDA, through large-scale online marketing has sparked controversy over both safety and legality.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.